BioSpace News Archive

Pharm Country

Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent® (alirocumab) Injection significantly reduced the risk of major adverse cardiovascular events (MACE) in patients who had suffered a recent acute coronary syndrome (ACS) event, such as a heart attack.

March 10, 2018
·
6 min read
Business

Clinical trial finds Philips’ instant wave-free ratio (iFR) more cost-effective than fractional flow reserve (FFR) in the guidance of percutaneous coronary intervention (PCI) for heart disease

Royal Philips today announced health economic results from the DEFINE FLAIR clinical trial comparing cost-effectiveness between instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the guidance of treatment of ischemic heart disease at the American College of Cardiology (ACC) annual meeting in Orlando, Florida, March 10-12, 2018.

March 10, 2018
·
3 min read
Pharm Country

Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need

Sanofi and Regeneron Pharmaceuticals, will offer U.S. payers that agree to reduce burdensome access barriers for high-risk patients a further reduced net price for Praluent® (alirocumab) Injection in alignment with a new value assessment for high-risk patients from the U.S. Institute for Clinical and Economic Review (ICER).

March 10, 2018
·
5 min read
Business

New Late-Breaking Study Finds Wearable Electrocardiogram (ECG) Monitoring Patch Can Detect Atrial Fibrillation Earlier and More Efficiently than Routine Care

The Janssen Pharmaceutical Companies of Johnson & Johnson announced late-breaking results of a new home-based clinical trial showing that a wearable continuous electrocardiogram (ECG) monitoring patch can identify people with asymptomatic atrial fibrillation (AFib) earlier and more efficiently than routine care.

March 10, 2018
·
7 min read